Overview: Multiple Myeloma MRD Monitoring Panel
Introduction: The Multiple Myeloma MRD Monitoring Panel is a diagnostic tool designed to monitor multiple myeloma residual disease using whole blood or bone marrow samples. In India, multiple myeloma affects ~10,000â€"15,000 new cases/year, with MRD negativity (flow/PCR <10^-5) post-induction/ASCT strongly predicting prolonged progression-free and overall survival. High morbidity from under-monitoring in rural/low-SES patients post-therapy, limited molecular/flow labs, delayed detection of relapse leading to end-organ damage or poor salvage response. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs PCR for myeloma-specific markers (IGH rearrangements, IGK, clonal sequences) and MRD quantification over 1-2 days with high sensitivity, valuable for assessing deep response in transplant-eligible patients. This diagnostic falls under leukemia monitoring and targets MM patients in remission or post-treatment, addressing accurate detection to guide maintenance therapy duration or early relapse intervention. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise MRD assessment and improving myeloma outcomes. Its blood/bone marrow-based approach ensures reliable quantification.
Other Names: MM MRD Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/hematology/oncology, compliant with 2025 standards.
Historical Milestone: MRD PCR in MM standard since 2010s; in India, expanding in myeloma centers.
Purpose: The test assesses 2 parameters including myeloma-specific markers to guide MRD monitoring, detect residual disease, inform therapy adjustment.
Test Parameters: 1. Myeloma-Specific Markers, 2. MRD Quantification.
Pretest Condition: No fasting required; patients should be MM in remission or post-treatment.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on treatment phase, prior MRD.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected MRD including relapse, benefits of monitoring, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and quantify MRD within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low disease burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Detectable MRD indicates high relapse risk, necessitating specialist input.
Specialist Consultation: Hematologists/oncologists should be consulted for management.
Additional Supporting Tests: Flow cytometry MRD, serum FLC for confirmation.
Test Limitations: Marker-specific; comprehensive approach required.
References: Indian Journal of Hematology 2024, Myeloma Studies India 2023.
